Aleutian Therapeutics
Organisation
People
Sources: reporter.nih.gov
Grants and prizes
National Institute of Diabetes and Digestive and Kidney Diseases
R41, Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapy, R41DK142395, US$372.1k, 2025–2027, 6 Sept 2025
National Institute of Allergy and Infectious Diseases
R41, Development of a gene edited platform to enable human allogeneic cell replacement therapy, R41AI192172, US$305.9k, 2025–2026, 18 Aug 2025
National Institute of Allergy and Infectious Diseases
R41, Development of immune evasive strategies for allogeneic cell replacement therapies, R41AI191979, US$307.1k, 2025–2026, 21 May 2025
Sources: reporter.nih.gov